scholarly journals WS01.5 An open-label study of the safety, pharmacokinetics, and pharmacodynamics of ivacaftor in patients aged 2 to 5 years with cystic fibrosis and a CFTR gating mutation: The KIWI study

2015 ◽  
Vol 14 ◽  
pp. S2 ◽  
Author(s):  
M. Rosenfeld ◽  
S. Robertson ◽  
Y. Green ◽  
J. Cooke ◽  
A. Lawal ◽  
...  
Keyword(s):  
Cystic Fibrosis ◽  
Pharmacokinetics And Pharmacodynamics ◽  
Open Label ◽  
Open Label Study ◽  
Label Study

scholarly journals 55 Lumacaftor/ivacaftor (LUM/IVA) in patients (pts) with cystic fibrosis (CF) and advanced lung disease homozygous for F508del-CFTR: a 24-week open-label study

2017 ◽  
Vol 16 ◽  
pp. S78 ◽  
Author(s):  
J. Taylor-Cousar ◽  
M. Jain ◽  
T.L. Barto ◽  
T. Haddad ◽  
J. Atkinson ◽  
...  
Keyword(s):  
Cystic Fibrosis ◽  
Lung Disease ◽  
Open Label ◽  
Open Label Study ◽  
Label Study

scholarly journals WS7.5 Interim results of the phase 3 open-label study of ataluren in nonsense mutation cystic fibrosis (nmCF)

2013 ◽  
Vol 12 ◽  
pp. S15 ◽  
Author(s):  
E. Kerem ◽  
M. Wilschanski ◽  
I. Sermet-Gaudelus ◽  
K. De Boeck ◽  
F.J. Accurso ◽  
...  
Keyword(s):  
Cystic Fibrosis ◽  
Nonsense Mutation ◽  
Open Label ◽  
Phase 3 ◽  
Open Label Study ◽  
Label Study

scholarly journals Open label study of inhaled aztreonam for Pseudomonas eradication in children with cystic fibrosis: The ALPINE study

2015 ◽  
Vol 14 (1) ◽  
pp. 111-119 ◽  
Author(s):  
H.A.W.M. Tiddens ◽  
K. De Boeck ◽  
J.P. Clancy ◽  
M. Fayon ◽  
Arets H.G.M. ◽  
...  
Keyword(s):  
Cystic Fibrosis ◽  
Open Label ◽  
Open Label Study ◽  
Label Study
Sign in / Sign up

Export Citation Format

Share Document